Safety profile of riluzole (Rilutek®) in the treatment of amyotrophic lateral sclerosis;Etude de tolerance du riluzole (Rilutek®) dans le traitement de la sclerose laterale amyotrophique

Therapie

Volumn 55, Issue 2, 2000, Pages 303-312

  Roch Torreilles, I ^a   Camu, W ^b   Hillaire Buys, D ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Amyotrophic lateral sclerosis; Follow up; Pharmacovigilance; Riluzole; Safety

Indexed keywords

ANTICONVULSIVE AGENT; RILUZOLE; NEUROPROTECTIVE AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTHENIA; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; SKIN DISEASE; AGED; CLINICAL TRIAL; MIDDLE AGED; POSTMARKETING SURVEILLANCE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PRODUCT SURVEILLANCE, POSTMARKETING; RILUZOLE;

EID: 0034151705     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Meininger V. La sclérose latérale amyotrophique. Concours Med 1995; 117: 1216-1219.
2. 10, 5-1986.
3. Gastaut JL. The viral hypothesis. Adv Neurol 1995; 68: 135-137.
4. Mitchell JD. Heavy metals and trace elements in amyotrophic lateral sclerosis. Neurol Clin 1987; 5: 43-60.
5. Vincetti M, Guidetti D, Pinotti M et al. Amyotrophic lateral sclerosis after long-term exposure to drinking water with high selenium content. Epidemiology 1996; 7: 529-532.
6. Harris W. The traumatic factor in organic nervous disease. BMJ 1993; 2: 955-960.
7. Appel SH. An unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer's disease. Ann Neurol 1981; 10: 499-505.
8. Duberley RM, Johnson IP, Anand P et al. Ciliary neurotrophic factor receptor expression in spinal cord and motor cortex in amyotrophic lateral sclerosis. J Neurol Sci 1995; 129 (suppl): 109-113.
9. Julien JP. A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem Cell Biol 1995; 73: 593-597.
10. Figlewicz DA, Krizus A, Martinoli MG et al. Variants of the heavy neurofilament subunit are associated with development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3: 1757-1761.
11. Smith RG, Hamilton S, Hofmann F et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 1992; 327: 1721-1728.
12. Fishman PS, Shy ME, Hart DE et al. Antibodies to the ganglioside GD1b in a patient with motor neurone disease and thyroid adenoma. Arch Neurol 1991; 48: 1188-1190.
13. Siddique T, Figlewicz DA, Pericak-Vance MA et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 1991; 324: 1381-1384.
14. Deng HX, Hentati A, Tainer JA et al. Amyotrophic lateral sclerosis and structural defects in Cu/Zn superoxide dismutase. Science 1993; 261: 1047-1051.
15. Rothstein JD, Tsai G, Kuncl RW et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18-25.
16. Shaw PJ, Forrest V, Ince PG et al. CSF and plasma amino acid levels in motor neurone disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995; 4: 209-216.
17. Choi DW. Glutamate neurotoxicity and disease of the nervous system. Neuron 1988; 1: 623-634.
18. Meininger V. Traitement de la sclérose amyotrophique. Rev Prat 1989; 39: 1237-1240.
19. Rozier A, Ruskone-Fourmestraux A, Rosenbaum A et al. Place de la gastrostomie endoscopique percutanée dans la sclérose latérale amyotrophique. Rev Neurol 1991; 147: 174-176.
20. Bouche P, Castaigne P, Meininger V. Approches de la prise en charge dans la sclérose latérale amyotrophique. Rev Neurol 1989; 145: 49-54.
21. Mazzini L, Testa D, Balzarini C, Mora G. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol 1994; 241: 223-227.
22. Louwerse ES, Weverling GJ, Bossyut PM et al. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995; 52: 559-564.
23. Vyth A, Timmer JG, Bossuyt PM et al. Survival in patients with amyotrophic lateral sclerosis, treated with an array of anti-oxydants. J Neurol Sci 1996; 139(suppl.): 99-103.
24. Miller RG, Petajan JH, Bryan WW et al. A placebo controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 256-260.
25. Smith RA, Melmed S, Sherman B et al. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve 1993; 16: 624-633.
26. Borasio GD, Robberecht W, Leigh PN et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51: 583-586.
27. Munsat TL, Taft J, Jackson IM et al. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology 1992; 42: 1049-1053.
28. Smith SA, Miller RG, Murphy JR, Ringel SP. Treatment of ALS with high dose pulse cyclophosphamide. J Neurol Sci 1994; 124(suppl.): 84-87.
29. Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol 1996; 243: 117-120.
30. The Italian ALS study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure. Neurology 1993; 43: 2466-2470.
31. Miller RG, Moore D, Young LA et al. Placebo-controlled trial of gabapentine in patients with amyotrophic lateral sclerosis. Neurology 1996; 47: 1383-1388.
32. Askmark H, Aquilonius SM, Gillberg PG et al. A pilot trial of dextrometorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 197-200.
33. Eisen A, Stewart H, Schulzer M, Cameron D. Antiglutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993; 20: 297-301.
34. Blin O, Pouget J, Aubrespy G et al. A double-blind, placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis. J Neurol 1992; 239: 79-81.
35. Cheramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 1992; 147: 209-212.
36. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflügen Arch 1991; 419: 603-609.
37. Debono MW, Le Guern J, Canton T et al. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993; 235: 283-289.
38. Girdlestone D, Dupuy A, Coston A et al. Riluzole antagonizes excitatory amino acid-evoked firing in rat facial motor neurons in vivo. Br J Pharmacol 1989; 97(suppl.): 583.
39. Hubert JP, Delumeau JC, Glowinski J, Premont J. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994; 113: 261-267.
40. Peluffo H, Estevez A, Barbeito L, Stutzmann JM. Riluzole promotes survival of rat motoneurons in vitro by stimulating trophic activity produced by spinal astrocyte monolayers. Neurosci Lett 1997; 228: 207-211.
41. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-591.
42. Lacomblez L, Bensimon G, Leigh PN et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-1431.
43. Remy AJ, Camu W, Ramos J et al. Acute hepatitis after riluzole administration. J Hepatol 1999; 30: 527-530.
44. Castells L, Gamez J, Cervera C, Guardia J. Icteric toxic hepatitis associated with riluzole. Lancet 1998; 351: 648.
45. Berson A, Fromenty B, Letteron P, Pessayre D. Role of mitochondria in drug-induced hepatotoxicity. Gastroenterol Clin Biol 1998; 22: 59-72.
46. Fraysse S, Joly P. Dermatose huileuse de l'adulte. Orientation diagnostique. Rev Prat 1996; 46: 1409-1414.
47. Heid E. La dermite séborrhéique. Rev Prat 1993; 210: 29-34.
48. Assal F, Spahr L, Hadengue A et al. Tolcapone and fulminant hepatitis (letter). Lancet 1998; 352: 958.